

Drug Policy:

Xpovio™ (selinexor)

POLICY NUMBER UM ONC_1365	SUBJECT Xpovio™ (selinexor)	DEPT/PROGRAM UM Dept	PAGE 1 of 3
DATES COMMITTEE REVIEWED 08/14/19, 12/11/19, 05/13/20, 07/08/20, 02/10/21, 05/12/21, 11/15/21, 03/09/22, 05/11/22, 06/08/22, 01/11/23, 03/08/23	APPROVAL DATE March 8, 2023	EFFECTIVE DATE March 31, 2023	COMMITTEE APPROVAL DATES 08/14/19, 12/11/19, 05/13/20, 07/08/20, 02/10/21, 05/12/21, 11/15/21, 03/09/22, 05/11/22, 06/08/22, 01/11/23, 03/08/23
PRIMARY BUSINESS OWNER: UM		COMMITTEE/BOARD APPROVAL Utilization Management Committee	
URAC STANDARDS HUM v8: UM 1-2; UM 2-1	NCQA STANDARDS UM 2	ADDITIONAL AREAS OF IMPACT	
CMS REQUIREMENTS	STATE/FEDERAL REQUIREMENTS	APPLICABLE LINES OF BUSINESS Commercial, Exchange, Medicaid	

I. PURPOSE

To define and describe the accepted indications for Xpovio (selinexor) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century Health (NCH) is responsible for processing all medication requests from network ordering providers. Medications not authorized by NCH may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. Continuation requests for a not-approvable medication shall be exempt from this NCH policy provided:

1. The requested medication was used within the last year, **AND**
2. The member has not experienced disease progression and/or no intolerance to the requested medication, **AND**
3. Additional medication(s) are not being added to the continuation request.

B. Diffuse Large B-cell Lymphoma (DLBCL)

1. Xpovio (selinexor) may be used as a single agent in a member with relapsed/refractory diffuse large B-Cell Lymphoma who has documented disease progression on 2 or more lines of therapy AND has either failed autologous stem-cell transplant or was not eligible/suitable (based on clinical assessment) for an autologous stem-cell transplant.

C. Multiple Myeloma

1. Xpovio (selinexor) may be used in combination with Dexamethasone (unless there is a contraindication or intolerance to Dexamethasone or another corticosteroid) for a member with relapsed/refractory multiple myeloma who has documented disease progression on at least 4 prior lines of therapy including two proteasome inhibitors (e.g., bortezomib, carfilzomib, ixazomib), two immunomodulatory agents (e.g., lenalidomide, thalidomide, pomalidomide), and an anti-CD38 monoclonal antibody [e.g., Darzalex (daratumumab) or Sarclisa (isatuximab-irfc)] OR
2. Xpovio (selinexor) may be used for relapsed/refractory multiple myeloma in combination with Bortezomib +/- Dexamethasone in members who have received one prior therapy.
3. NOTE: Per NCH Policy, Selinexor + Daratumumab +/- Dexamethasone is not approvable for the treatment of relapsed/refractory MM. This Policy Position is based on the lack of Level 1 Evidence (randomized clinical trial and/or meta-analyses) to show superior outcomes with the above regimen compared to the NCH recommended alternatives agents/regimens, including but not limited to regimens at <http://pathways.newcenturyhealth.com>.

III. EXCLUSION CRITERIA

- A. Disease progression while receiving Xpovio (selinexor).
- B. Dosing exceeds single dose limit of Xpovio (selinexor) 60 mg (for DLBCL) or 100 mg (for MM).
- C. Treatment exceeds the maximum limit of 32 (20 mg), 16 (40 mg), 8 (50 mg), 8 (60mg) tablets/month.
- D. Investigational use of Xpovio (selinexor) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
 1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
 2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
 3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
 4. Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
 5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
 6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.

7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

VI. ATTACHMENTS

- A. None

VII. REFERENCES

- A. Chari A, et al. STORM Trial. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019 Aug 22;381(8):727-738.
- B. Kalakonda N, et al. SADAL Trial. Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020 Jul;7(7):e511-e522.
- C. Xpovio prescribing information. Karyopharm Therapeutics Inc. Newton, MA 2023.
- D. Clinical Pharmacology Elsevier Gold Standard 2023.
- E. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2023.
- F. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2023.
- G. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs Bethesda, MD 2023.
- H. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20;32(12):1277-80.
- I. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.
- J. NCQA UM 2023 Standards and Elements.